Compare General Dynamics Corporation (GD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Recursion Pharmaceuticals Inc — how do they compare? General Dynamics Corporation trades at $334 (market cap $89.26B), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: General Dynamics Corporation is far larger — about 41.7× Recursion Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GD | RXRX | |
|---|---|---|
Market Cap | $89.26B | $2.14B |
Volume | 1,496,273 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $395.97 | $6.79 |
52-Week Low | $312.53 | $2.84 |
Typical Hold Time | 85 Days | 23 Days |
Enterprise Value | $94.40B | $1.66B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.27, up 1.42% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 8.18% net margins and 17.8% ROE. Recent defense spending trends and analyst consensus of $420.57 price target suggest upside potential despite current technical weakness.
GD presents a compelling value opportunity with consistent earnings beats and strong defense sector tailwinds. Key risks include defense budget volatility and competitive pressures, but the company's $1.59 dividend and improving cash flow trends support the bullish analyst outlook. The stock's current discount to consensus target offers potential for appreciation.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
